» Articles » PMID: 23220414

Regional Vulnerability in Huntington's Disease: FMRI-guided Molecular Analysis in Patients and a Mouse Model of Disease

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2012 Dec 11
PMID 23220414
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Although the huntingtin gene is expressed in brain throughout life, phenotypically Huntington's disease (HD) begins only in midlife and affects specific brain regions. Here, to investigate regional vulnerability in the disease, we used functional magnetic resonance imaging (fMRI) to translationally link studies in patients with a mouse model of disease. Using fMRI, we mapped cerebral blood volume (CBV) in three groups: HD patients, symptom-free carriers of the huntingtin genetic mutation, and age-matched controls. In contrast to a region in the anterior caudate, in which dysfunction was linked to genotype independent of phenotype, a region in the posterior body of the caudate was differentially associated with disease phenotype. Guided by these observations, we harvested regions from the anterior and posterior body of the caudate in postmortem control and HD human brain tissue. Gene-expression profiling identified two molecules whose expression levels were most strongly correlated with regional vulnerability - protein phosphatase 1 regulatory subunit 7 (PPP1R7) and Wnt inhibitory factor-1 (WIF-1). To verify and potentially extend these findings, we turned to the YAC128 (C57BL/6J) HD transgenic mice. By fMRI we longitudinally mapped CBV in transgenic and wildtype (WT) mice, and over time, abnormally low fMRI signal emerged selectively in the dorsal striatum. A relatively unaffected brain region, primary somatosensory cortex (S1), was used as a control. Both dorsal striatum and S1 were harvested from transgenic and WT mice and molecular analysis confirmed that PPP1R7 deficiency was strongly correlated with the phenotype. Together, converging findings in human HD patients and this HD mouse model suggest a functional pattern of caudate vulnerability and that variation in expression levels of herein identified molecules correlate with this pattern of vulnerability.

Citing Articles

Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington's Disease: A Review of Data from Mouse Models.

Hanrahan J, Locke D, Cahill L J Huntingtons Dis. 2024; 13(3):279-299.

PMID: 39213087 PMC: 11494634. DOI: 10.3233/JHD-240045.


Brain-Periphery Interactions in Huntington's Disease: Mediators and Lifestyle Interventions.

Burtscher J, Strasser B, Pepe G, Burtscher M, Kopp M, Di Pardo A Int J Mol Sci. 2024; 25(9).

PMID: 38731912 PMC: 11083237. DOI: 10.3390/ijms25094696.


The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington's disease.

Perot J, Brouillet E, Flament J Front Aging Neurosci. 2024; 16:1306312.

PMID: 38414634 PMC: 10896846. DOI: 10.3389/fnagi.2024.1306312.


Deep learning of MRI contrast enhancement for mapping cerebral blood volume from single-modal non-contrast scans of aging and Alzheimer's disease brains.

Liu C, Zhu N, Sun H, Zhang J, Feng X, Gjerswold-Selleck S Front Aging Neurosci. 2022; 14:923673.

PMID: 36034139 PMC: 9407020. DOI: 10.3389/fnagi.2022.923673.


The Spatiotemporal Coupling: Regional Energy Failure and Aberrant Proteins in Neurodegenerative Diseases.

Virtuoso A, Colangelo A, Maggio N, Fennig U, Weinberg N, Papa M Int J Mol Sci. 2021; 22(21).

PMID: 34768733 PMC: 8583302. DOI: 10.3390/ijms222111304.


References
1.
Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K . A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001; 356(1412):1293-322. PMC: 1088516. DOI: 10.1098/rstb.2001.0915. View

2.
Bock N, Kovacevic N, Lipina T, Roder J, Ackerman S, Henkelman R . In vivo magnetic resonance imaging and semiautomated image analysis extend the brain phenotype for cdf/cdf mice. J Neurosci. 2006; 26(17):4455-9. PMC: 6674055. DOI: 10.1523/JNEUROSCI.5438-05.2006. View

3.
Yushkevich P, Piven J, Hazlett H, Smith R, Ho S, Gee J . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31(3):1116-28. DOI: 10.1016/j.neuroimage.2006.01.015. View

4.
Lin W, Celik A, Paczynski R . Regional cerebral blood volume: a comparison of the dynamic imaging and the steady state methods. J Magn Reson Imaging. 1999; 9(1):44-52. DOI: 10.1002/(sici)1522-2586(199901)9:1<44::aid-jmri6>3.0.co;2-7. View

5.
Gaisler-Salomon I, Miller G, Chuhma N, Lee S, Zhang H, Ghoddoussi F . Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology. 2009; 34(10):2305-22. PMC: 2811085. DOI: 10.1038/npp.2009.58. View